A. Unaudited Financial Results for Q2 FY27

The Board approved the unaudited financial results for the quarter ended June 30, 2026.

  • Income: Total income was ₹144.93 Crores, comprising Revenue from Operations of ₹142.97 Crores and Other Income of ₹1.96 Crores.
  • Expenses: Total expenses were ₹113.97 Crores. Major expense line items include:
  • Employee benefits expense: ₹27.48 Crores
  • Other expenses: ₹22.42 Crores
  • Consultancy charges for doctors: ₹19.66 Crores
  • Consumption of surgical lenses & consumables: ₹16.55 Crores
  • Purchase of stock-in-trade: ₹14.66 Crores
  • Depreciation and amortisation: ₹11.49 Crores
  • Finance costs: ₹2.77 Crores
  • Profitability: Profit before tax stood at ₹30.96 Crores. After a total tax expense of ₹7.58 Crores, Net profit after tax was ₹23.38 Crores.
  • Earnings Per Share: Basic and Diluted EPS were both ₹48.38 (not annualised).
  • EBITDA: Earnings before Finance cost, Depreciation, amortisation and Tax was ₹45.22 Crores.
  • Comprehensive Income: Total comprehensive income for the period was ₹22.91 Crores.
  • Capital Structure: Paid-up equity share capital (Face value ₹10 each) was ₹4.83 Crores.

The financial results were reviewed by the statutory auditors, S.R. Batliboi & Associates LLP, who issued an unmodified conclusion. The results will be published in newspapers per Regulation 47 and are available on the company's website www.dragarwals.co.in.

B. Re-appointment of Cost Auditors

The Board re-appointed M/s. B Y & Associates, Practicing Cost Accountants (Firm Registration No. 003498), as the Cost Auditors for the financial year 2026-27. This re-appointment was recommended by the Audit Committee and is in accordance with Section 148 of the Companies Act, 2013. The term of appointment is till the earlier of 180 days from the closure of FY 2026-27 or the submission of the cost audit report.

Additional Disclosures from Notes to Accounts

  • Segment Information: The company operates in a single segment: "Eye Care related sales and services".
  • Amalgamation Scheme: A scheme of amalgamation with the holding company, Dr. Agarwal's Health Care Limited (AHCL), was approved by the Board on August 27, 2025. Meetings of equity shareholders, secured creditors, and unsecured creditors of both companies were held on July 02, 2026, following an NCLT Chennai Bench order dated May 05, 2026. The resolutions were approved by the requisite majority. The scheme remains subject to final sanction from the Hon'ble NCLT.
  • Preferential Allotment: The Board had approved the issuance of 1,32,827 equity shares (face value ₹10 each) at ₹5,270 per share to AHCL by way of a preferential issue amounting to ₹70 Crores. This was approved by shareholders on September 24, 2025, and shares were allotted on September 26, 2025. Listing and trading approvals were received on October 16, 2025, and October 28, 2025, respectively. As of June 30, 2026, ₹28.20 Crores of the proceeds had been utilized as per the objects, with the unutilized balance temporarily invested in debt mutual funds.
  • Subsidiaries: The company does not have any subsidiary, associate, or joint venture entity.

Meeting Details

The board meeting commenced at 03:00 P.M. IST and concluded at 03:45 P.M. IST on August 03, 2026.